The Carboxyl-Terminus of Human Immunodeficiency Virus Type 2 Circulating Recombinant form 01_AB Capsid Protein Affects Sensitivity to Human TRIM5α
暂无分享,去创建一个
J. Luban | W. Sugiura | T. Miyamoto | T. Shioda | K. Kono | M. Yokoyama | Hironori Sato | Y. Yokomaku | M. Pizzato | E. Nakayama | S. Ibe | Shunpei Takehara
[1] A. Mitra,et al. A structural model for the generation of continuous curvature on the surface of a retroviral capsid. , 2012, Journal of molecular biology.
[2] T. Miyamoto,et al. A Single Amino Acid of Human Immunodeficiency Virus Type 2 Capsid Protein Affects Conformation of Two External Loops and Viral Sensitivity to TRIM5α , 2011, PloS one.
[3] J. Luban,et al. Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon , 2011, Retrovirology.
[4] Jeremy Luban,et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice , 2011, Nature.
[5] A. Ryo,et al. A structural constraint for functional interaction between N-terminal and C-terminal domains in simian immunodeficiency virus capsid proteins , 2010, Retrovirology.
[6] T. Shioda,et al. Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5α-mediated restriction , 2010, Retrovirology.
[7] W. Sugiura,et al. HIV-2 CRF01_AB: First Circulating Recombinant Form of HIV-2 , 2010, Journal of acquired immune deficiency syndromes.
[8] T. Shioda,et al. Anti‐retroviral activity of TRIM5α , 2010, Reviews in medical virology.
[9] S. Rowland-Jones,et al. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. , 2009, Vaccine.
[10] L. James,et al. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp , 2009, Nature Structural &Molecular Biology.
[11] Mark Yeager,et al. X-Ray Structures of the Hexameric Building Block of the HIV Capsid , 2009, Cell.
[12] Toshihiro Sato,et al. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif , 2008, Nature Structural &Molecular Biology.
[13] T. Shioda,et al. Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection. , 2008, Virology.
[14] Mark Yeager,et al. The structural biology of HIV assembly. , 2008, Current opinion in structural biology.
[15] David P Lane,et al. Molecular simulations of protein dynamics: new windows on mechanisms in biology , 2008, EMBO reports.
[16] J. Levy,et al. A Single Amino Acid of the Human Immunodeficiency Virus Type 2 Capsid Affects Its Replication in the Presence of Cynomolgus Monkey and Human TRIM5αs , 2007, Journal of Virology.
[17] S. Rowland-Jones,et al. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? , 2007, Nature Immunology.
[18] J. Levy,et al. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. , 2007, Journal of virology.
[19] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[20] A. Engelman,et al. Proteasome Inhibition Reveals that a Functional Preintegration Complex Intermediate Can Be Generated during Restriction by Diverse TRIM5 Proteins , 2006, Journal of Virology.
[21] T. Hope,et al. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] Joseph Sodroski,et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Luban,et al. Cyclophilin A and TRIM5α Independently Regulate Human Immunodeficiency Virus Type 1 Infectivity in Human Cells , 2006, Journal of Virology.
[24] Y. Nagai,et al. A Specific Region of 37 Amino Acid Residues in the SPRY (B30.2) Domain of African Green Monkey TRIM5α Determines Species-Specific Restriction of Simian Immunodeficiency Virus SIVmac Infection , 2005, Journal of Virology.
[25] J. Luban,et al. TRIM5α selectively binds a restriction-sensitive retroviral capsid , 2005, Retrovirology.
[26] K. Ikuta,et al. Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor , 2005, Journal of Virology.
[27] J. Sodroski,et al. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] G. Towers,et al. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] A. Yang,et al. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] F. Brun-Vézinet,et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. , 2004, AIDS research and human retroviruses.
[31] C. M. Owens,et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.
[32] J. Ponder,et al. Force fields for protein simulations. , 2003, Advances in protein chemistry.
[33] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[34] G. Gottlieb,et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. , 2002, The Journal of infectious diseases.
[35] A. Sali,et al. Protein Structure Prediction and Structural Genomics , 2001, Science.
[36] Alessandro Guffanti,et al. The tripartite motif family identifies cell compartments , 2001, The EMBO journal.
[37] C. K. Chu,et al. Molecular Modeling Approach to Understanding the Mode of Action of l-Nucleosides as Antiviral Agents , 2001, Antimicrobial Agents and Chemotherapy.
[38] F. Gao,et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes , 1999, Nature.
[39] W. Sundquist,et al. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. , 1997, Science.
[40] I. Thior,et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. , 1994, Science.
[41] J. Bull,et al. An Empirical Test of Bootstrapping as a Method for Assessing Confidence in Phylogenetic Analysis , 1993 .
[42] G. Nolan,et al. Production of high-titer helper-free retroviruses by transient transfection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[43] F. Gao,et al. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa , 1992, Nature.
[44] Andreas Meyerhans,et al. Genetic organization of a chimpanzee lentivirus related to HIV-1 , 1990, Nature.
[45] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[46] A. Dion,et al. Experimental infection of a cat kidney cell line with the mouse mammary tumor virus. , 1976, Cancer research.